Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis
EstadísticasView Usage Statistics
Full recordShow full item record
AuthorRemuzgo Martínez, Sara; Genre, Fernanda; Castañeda, Santos; Corrales Martínez, Alfonso; Moreno Fresneda, Pablo; Ubilla García, Begoña; Mijares Díaz, Verónica; Portilla González, Virginia; González Vela, Jesús; Pina Murcia, Trinitario; Ocejo Viñals, Javier Gonzalo; Irure Ventura, Juan; Blanco Alonso, Ricardo; Martín, Javier; Llorca Díaz, Francisco Javier; López Mejías, Raquel; González-Gay Mantecón, Miguel Ángel
Several protein tyrosine phosphatase non-receptor 22 (PTPN22) single-nucleotide polymorphisms (SNPs) have been significantly related with rheumatoid arthritis (RA) susceptibility. Nevertheless, its potential influence on PTPN22 expression in RA has not been completely elucidated. Furthermore, PTPN22 binds to C-Src tyrosine kinase (CSK) forming a key complex in autoimmunity. However, the information of CSK gene in RA is scarce. In this study, we analyzed the relative PTPN22 and CSK expression in peripheral blood from 89 RA patients and 43 controls to determine if the most relevant PTPN22 (rs2488457, rs2476601 and rs33996649) and CSK (rs34933034 and rs1378942) polymorphisms may influence on PTPN22 and CSK expression in RA. The association between PTPN22 and CSK expression in RA patients and their clinical characteristics was also evaluated. Our study shows for the first time a marked down-regulation of PTPN22 expression in RA patients carrying the risk alleles of PTPN22 rs2488457 and rs2476601 compared to controls (p?=?0.004 and p?=?0.007, respectively). Furthermore, CSK expression was significantly lower in RA patients than in controls (p?<?0.0001). Interestingly, a reduced PTPN22 expression was disclosed in RA patients with ischemic heart disease (p?=?0.009). The transcriptional suppression of this PTPN22/CSK complex may have a noteworthy clinical relevance in RA patients.